The tablets are a new formulation of the drug lorcaserin, which is intended to help patients achieve and maintain weight loss when paired with a reduced-calorie diet and increased physical activity.
Arena, which entered into a licensing agreement with Tokyo-based Eisai in 2010, will receive a $10 million milestone payment for the approval.
Belviq XR is expected to reach the market in fall 2016.
More articles on the drug market:
PhRMA adds 5 new companies to its ranks, including generic rival Teva
Roche’s blood cancer drug disappoints in clinical trial
FDA approves Aurobindo’s new pain med
